Key clinical point: Starting a PCSK9 inhibitor plus a high-intensity statin soon after patients presented with acute-phase acute coronary syndrome proved to be a safe and well tolerated means of achieving massive LDL cholesterol lowering.
Major finding: Starting evolocumab plus high-intensity atorvastatin soon after patients presented with acute-phase acute coronary syndrome safely resulted in an LDL cholesterol reduction from 132 mg/dL to 31 mg/dL 8 weeks later.
Study details: This was a randomized trial of evolocumab or placebo injections plus high-intensity atorvastatin started during acute-phase acute coronary syndrome.
Disclosures: The EVOPACS study was sponsored by Amgen. The presenter reported receiving honoraria from Amgen and Sanofi.
Koskinas KC. ESC 2019, Abstract 82.